<code id='5376C800F8'></code><style id='5376C800F8'></style>
    • <acronym id='5376C800F8'></acronym>
      <center id='5376C800F8'><center id='5376C800F8'><tfoot id='5376C800F8'></tfoot></center><abbr id='5376C800F8'><dir id='5376C800F8'><tfoot id='5376C800F8'></tfoot><noframes id='5376C800F8'>

    • <optgroup id='5376C800F8'><strike id='5376C800F8'><sup id='5376C800F8'></sup></strike><code id='5376C800F8'></code></optgroup>
        1. <b id='5376C800F8'><label id='5376C800F8'><select id='5376C800F8'><dt id='5376C800F8'><span id='5376C800F8'></span></dt></select></label></b><u id='5376C800F8'></u>
          <i id='5376C800F8'><strike id='5376C800F8'><tt id='5376C800F8'><pre id='5376C800F8'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:6868
          illustration of one blue dna strand
          Adobe

          The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

          Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

          advertisement

          Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          Biden announces an advanced cancer research initiative
          Biden announces an advanced cancer research initiative

          PresidentBidenspeaksintheEastRoomoftheWhiteHouseonTuesday.SusanWalsh/APWASHINGTON—PresidentBiden’sad

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Biogen nominates mother of director’s child to replace him on board

          StevenSenn/APBiogen,abiotechgiantplaguedbyyearsofboardroomstrife,saidlateMondaythatthelongtimeandpol